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Aims Bone marrow (BM)-derived endothelial progenitor cells (EPCs) in the circulation replace damaged
vascular endothelium. We assessed the hypothesis that a BM transplant from healthy animals would
restore normal arterial endothelium and prevent hypertension in young endothelial nitric oxide
synthase-deﬁcient (eNOS
2/2) mice.
Methods and results Radiation or busulfan-induced BM ablation in eNOS
2/2 mice on day 6, day 14, or
day 28 was followed by a BM transplant consisting of enhanced green ﬂuorescent protein positive
(EGFP
þ) cells from C57BL/6J mice. Peripheral blood cell chimerism was always greater than 85% at
4 months after BM transplant. Molecular assays of heart, kidney, and liver revealed low-level chimerism
in all treatment groups, consistent with residual circulating EGFP
þ blood cells. When aorta, coronary,
renal, hepatic, and splenic arteries in BM-transplanted eNOS
2/2 mice were examined by confocal
microscopy, there were no EGFP- or eNOS-positive endothelial cells detected in these vessels in any
of the treatment groups. Likewise, telemetry did not detect any reduction in blood pressure. Thus,
no differences were observed in our measurements using several different treatment protocols.
Conclusion We found no evidence for BM-derived EPC renewal of endothelium in this eNOS-deﬁcient
mouse model of a chronic vascular disease or in wild-type mice during postnatal growth. Hence,
renewal of chronic dysfunctional endothelium and endothelial homeostasis may be dependent on resi-
dent vascular progenitor cells.
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1. Introduction
Recent evidence indicates that a population of progenitor
cells that exist in the circulation has the potential to
repair endothelium and maintain angiogenesis during post-
natal life. In human subjects, these cells, termed endo-
thelial progenitor cells (EPCs), can be mobilized in large
numbers from bone marrow (BM) by a single injection of
AMD3100, a CXCR4 antagonist,
1 and their number in blood
has been reported to correlate directly with vascular endo-
thelial function when measured by ﬂow-mediated brachial
artery reactivity.
2
In animal studies, BM-derived EPCs contribute to recovery
of the vascular system in response to tissue ischaemia result-
ing from intra-arterial trauma or arterial ligation.
3–7 Follow-
ing mobilization into the circulation, EPCs are recruited to
the traumatized or ischaemic tissues in response to secretion
of stromal cell-derived factor-1,
8,9 or vascular endothelial
growth factor.
10 Likewise, infusion of BM-derived mono-
nuclear cells into an acutely ischaemic hind-limb in mice †These two authors contributed equally to this study.
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11,12 Data from these and other
studies support the concept that a subpopulation of BM
cells promote vascular repair in acute injuries.
13,14
Whereas previous animal studies have relied mainly on
acute injury to demonstrate the contribution of BM-derived
EPCs to vascular biology, our investigation focused on
whether EPCs can replace dysfunctional endothelium in a
setting of chronic vascular disease. We hypothesized that
progenitor cells may be recruited from BM over time in
response to the chronic hypertension observed in endo-
thelial nitric oxide synthase-deﬁcient (eNOS
2/2) mice.
15
Further, we anticipated that early transplantation of
enhanced green ﬂuorescent protein positive (EGFP
þ),
eNOS
þ BM cells into day-6 and day-14 neonates and day-28
young adult mice might facilitate incorporation of donor-
derived progenitor cells into the expanding cardiovascular
system. We did not ﬁnd evidence for incorporation of any
donor-derived EGFP
þ eNOS
þ progenitor cells into the endo-
thelium of conducting arteries and arterioles, or prevention
of hypertension. Our study suggests that endothelial
renewal in homeostasis and in chronic dysfunctional states
is dependent upon progenitor cells that reside in or near
the arterial wall.
2. Methods
2.1 Animal model
All mice were obtained from Jackson Laboratories, Bar Harbor, ME,
USA. Enhanced GFP
þ C57BL/6-Tg(UBC_GFP)30Scha/J mice were
used as donors for BM transplantation in B6.129P2-Nos3tm1Unc/J
eNOS
2/2 mice. The investigation conforms to the Guide for the
Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No.85-23, revised 1996). All
animals were handled following the guidelines of the Animal Care
and Use Committee at the NHLBI, National Institutes of Health
(Animal Study Proposal H-0162).
2.2 Bone marrow harvest and transplantation
BM cells were harvested from the femurs and tibias of 2–4 month old
EGFP
þ donor mice and the nucleated cells were enriched by lysing
red blood cells with ACK buffer (Cambrex, Walkersville, MD, USA).
Total body sub-lethal radiation (6 Gy) was administered to day-6,
day-14, and day-28 eNOS
2/2 mice and 6 h later 2.5–3.0   10
7
EGFP
þ BM nucleated cells were injected intraperitoneally into day
6 and day 14 neonates or intravenously into day-28 young adult
mice. Non-treated transgenic EGFP
þ mice and wild-type (WT)
mice transplanted with EGFP
þ BM served as controls. There were
12 mice studied in these three experimental groups and 8 mice in
the two control groups. In an additional series of experiments, to
counter any possibility that lasting radiation-induced damage
might prevent arterial endothelium from responding to signals
that govern endothelial repair, we performed experiments using
the myeloablative agent busulfan. A single dose of busulfan was
administered to three day-13 and three day-27 mice at a dose of
20 gm/kg body weight. BM was transplanted 1 day later.
2.3 Cardiac ultrasound
Echocardiography was performed using the VisualSonics’ Vevo 770
w
(VisualSonics, Inc., Toronto, Ontario, Canada) equipped with a
15 MHz probe on mice at 4 months post-BM transplant and on age-
matched WT and eNOS
2/2 controls. Mice were kept under light
sedation with 1–2% isoﬂurane for the duration of the imaging
session. Images were obtained from short- and long-axis views of
the left ventricle. Two-dimensional and M-mode echocardiography
images were observed. Cardiac structures such as the thickness of
the interventricular septum and posterior wall, and the diameter
of the left ventricle were measured based on M-mode images, and
functional features [fractional shortening (FS), ejection fraction
(EF), cardiac output (CO), and stroke volume (SV)] were automati-
cally calculated with Vevo 770w software from structural values.
2.4 Flow cytometry
Blood was collected from the retro-orbital sinus of BM-transplanted
eNOS
2/2 recipient mice at 4 months post-transplant. Red blood
cells were lysed in ACK buffer and the remaining nucleated blood
cells were washed in phosphate-buffered saline (PBS) and analysed
for EGFP ﬂuorescence using a ﬂuorescence-activated cell sorter
(Calibur Instrument, BD Biosciences, San Jose, CA, USA). All
BM-transplanted eNOS
2/2 mice selected for further study showed
.85% chimerism at 4 months after transplantation.
2.5 Blood pressure monitoring
Blood pressure was measured in BM-transplanted eNOS
2/2 mice,
non-transplanted eNOS
2/2 controls, and WT controls by radiotele-
metry (Data Sciences International, St Paul, MN, USA). For implan-
tation of PA-C10 pressure transmitters, mice were anesthetized
with an intraperitoneal injection of 90 mg/kg ketamine and
10 mg/kg xylazine. The catheter was inserted through the left
carotid artery into the aortic arch with the transmitter body
tucked into a subcutaneous pocket of the right ﬂank. Mice were
returned to their cages the day after surgery, and were observed
for 7–10 days before the initial recordings. Mice had access to
food and water at all times, and the recording room was maintained
at an ambient temperature of 21–228C with a 12 h light/dark cycle.
The transmitter signal was captured using the RPC-1 receiver, a
20 channel data exchange matrix, APR-1 ambient pressure monitor,
and a Data Quest ART Silver 2.3 acquisition system (Data Sciences
International). Mean arterial pressure, systolic blood pressure,
diastolic blood pressure, pulse pressure, heart rate, and activity
values were recorded for 10 s at 2 min intervals and hourly
averages were calculated for each mouse during a period of 100
consecutive hours. The mean+SD was calculated for 17 WT
control mice, 4 non-treated eNOS
2/2 control mice, and 4
BM-transplanted eNOS
2/2 mice.
2.6 Western blot
Total protein from heart, kidney, and spleen was extracted using a
steel homogenizer ball (Restch, Newtown, PA, USA). Extracted
protein concentrations were determined by the bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL, USA). Protein samples
(20 mg) were resolved on a 4–20% Novex
w Tris-Glycine gel (Invitro-
gen, Carlsbad, CA, USA) and transferred to a nitrocellulose mem-
brane (Invitrogen) using an iBlotTM Dry Blotting system
(Invitrogen). The membrane was blocked with 5% skim milk in PBS
for 1 h at room temperature. Primary antibodies were rabbit
anti-EGFP (1:10,000, Invitrogen) and mouse anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; 1:500, Imgenex, San Diego,
CA, USA). The membrane was exposed to the primary antibodies
overnight at 48C, followed by three 5 min washes with Tris-buffered
saline containing 0.05% Tween 20. After washing, the membrane was
incubated with horseradish peroxidase conjugated goat anti-rabbit
or anti-mouse antibodies (Pierce) for 2 h at room temperature.
Enhanced chemiluminescence reaction was performed using a
SuperSignal
w West Femto enhancer kit (Pierce), according to the
manufacturer’s instructions.
2.7 Quantitative RT–PCR
Total RNAwas isolated from kidney, liver, and spleen and preserved in
RNAlater buffer (Ambion, Austin, TX, USA) following the manufac-
turer’s protocol in the RNeasy Mini Kit (Qiagen, Valencia, CA, USA).
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9700 (Applied Biosystems, Foster City, CA, USA) using the SuperScript
II RT–PCR Kit (Invitrogen). PCR was performed on the ABI Prism 7000
using TaqMan Universal PCR Master Mix and Assays-on-Demand Gene
Expression probes (Applied Biosystems) speciﬁc for eNOS, EGFP , and
ß-actin. Relative eNOS and EGFP mRNA levels were calculated using
a2
DDCt method.
2.8 DNA electrophoresis
Heart, kidney, and spleen were obtained for DNA analysis. DNA was
isolated following the manufacturer’s protocol for the DNeasy Tissue
Kit (Qiagen) and ampliﬁed with primers speciﬁc for eNOS and EGFP
on the GeneAmp PCR System 9700 (Applied Biosystems). To detect
eNOS, DNAwas ampliﬁed in Platinum Blue PCR SuperMix (Invitrogen)
with forward 50-ATTTCCTGTCCCCTGCCTTC-30, and reverse primers
50-GGCCAGTCTCAGAGCCATAC-30, and primer speciﬁc for the
neomycin-resistance gene insert 50-TGGCTACCCGTGATATTGCT-30.
These primers were designed to produce a 450 bp band consisting
of amplicons of the WT eNOS gene and a 500 bp band representing
amplicons consisting of 450 bp of the disrupted exon 12 of the
eNOS gene plus 50 bp of the targeting construct. To detect EGFP,
DNA was ampliﬁed using a HotStar Taq Polymerase Kit (Qiagen)
with primers 50-AAGTTCATCTGCACCACCG-30 and 50-TCCTTGAAGAA
GATGGTGCG-30 that generate a 200 bp product. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (250 bp) was used as a
loading control. DNA bands were isolated in 2% agarose gels.
2.9 Immunohistochemistry and confocal
microscopy
Tissues were ﬁxed in 4% formaldehyde and 5 mm parafﬁn sections
were prepared (HistoServ, Germantown, MD, USA). Rehydrated par-
afﬁn sections were submerged in boiling citrate buffer at pH 6.0 for
15 min in a microwave oven. Sections were allowed to cool in citrate
buffer for 30 min at room temperature. After washing, sections
were incubated with primary antibody for 1 h at 378C in a moist
chamber. We used the following antibodies: goat polyclonal to
EGFP (ab5450); rabbit polyclonal to smooth muscle alpha actin
(SMaA) (ab5694); rabbit polyclonal to von Willebrand Factor (vWF)
(ab6994) all from Abcam, Cambridge, MA, USA, and rabbit polyclo-
nal to NOS3 (eNOS) (sc-654) from Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA. Negative controls were not exposed to
primary antibody. After washing, sections were incubated with
secondary antibody conjugated to ﬂuorescein isothiocyanate or
Texas Red for 1 h at 378C in a moist chamber and then mounted
with Vectashield containing 40,6-diamidino-2-phenylindole (DAPI) a
stain for DNA. Images were obtained using a confocal microscope
(Leica SP1; Leica Microsystems, Heidelberg, Germany) equipped
with an Ar/Kr/HeNe laser combination. Photographs were taken
with Leica confocal software. For controls, there were ﬁve EGFP
þ
mice and three WT mice that were BM-transplanted on day 28.
Experimental mice included 12 eNOS
2/2 mice in three categories
of radiation treatment: ﬁve were irradiated and transplanted on
day 6, two were transplanted on day 14, and ﬁve on day 28. In
addition, three eNOS
2/2 mice were myeloablated with busulfan
on day 13 and transplanted on day 14, and three were myeloablated
on day 27 and transplanted on day 28. All forms of treatment
resulted in comparable high-level reconstitution of splenic and
medullary haematopoiesis and no incorporation of donor cells into
arterial endothelium. For each animal we ﬁxed and embedded a
portion of heart, kidney, liver, and spleen, and for some we also
examined aorta, lung, small intestine, skin, and skeletal muscle.
Heart, kidney, liver, and spleen from each mouse were embedded
in one block and from each block, ﬁve or more slides (range 5–14,
total of 124 slides) were prepared. Two sections, each 5 mm thick,
were mounted per slide. One section was stained for EGFP and
either SMaA, vWF, or eNOS and examined for donor cell incorpor-
ation into arterial endothelium. The other section served as a
negative control and was stained only with secondary antibodies.
For each organ on each slide, we examined one or more large
conduit arteries and 5–20 arterioles for incorporation of EGFP
þ
endothelial cells.
2.10 Statistical analysis
GraphPad Prism 4 (GraphPad Software, Inc., San Diego, CA, USA)
was used to calculate one-way analyses of variance (ANOVA).
When P , 0.05, Tukey’s multiple comparison post hoc tests were
performed to determine the source of variance (P , 0.05). When
calculating data from qRT–PCR for eNOS and EGFP expression,
unpaired, independent Student’s t-test was performed to obtain
P-values. In addition, Student’s t-test was performed to calculate
P-values using an EXCEL program (Microsoft 2003).
3. Results
3.1 Chimerism in transplanted mice
Chimerism in transplanted eNOS
2/2 mice was determined
by the percentage of EGFP
þ nucleated blood cells found in
peripheral blood at 4 months post-transplant (Figure 1A).
Mice showing greater than 85% chimerism were used for
further study.
3.2 Body weight
Body weight for BM-transplanted eNOS
2/2 mice and non-
BM-transplanted eNOS
2/2 control mice was obtained to
ascertain possible effects of treatment on growth and devel-
opment. Mice in the non-transplanted eNOS
2/2 control
group (20+1 gm) and in the BM-transplanted eNOS
2/2
group (21+1 gm) had signiﬁcantly lower body weight
than WT mice (24+1 gm) (P , 0.05). The BM-transplanted
eNOS
2/2 group showed a small but not signiﬁcant increase
in weight compared with the eNOS
2/2 control group.
3.3 Cardiac structure and function
Cardiac ultrasound was performed on WT, non-transplanted
eNOS
2/2 age-matched controls and BM-transplanted
mice at 4 months post-transplantation to observe any
changes in cardiac structures or functions resulting from
procedures associated with the BM transplant (Supplemen-
tary material online, Table S1). Control eNOS
2/2 mice and
BM-transplanted eNOS
2/2 mice exhibited a decreased thick-
ness of the interventricular septum in diastole (IVSd) and
systole (IVSs) compared with WT controls (P , 0.05).
However, left ventricle posterior wall thickness was compar-
able among all three groups. Likewise, the left ventricle
internal diameter in eNOS
2/2 controls and BM-transplanted
eNOS
2/2 mice did not differ in diastole and systole com-
pared with WT control mice. Cardiac functions such as FS,
SV, EF, and CO obtained for WT controls, eNOS
2/2 mice,
and BM-transplanted eNOS
2/2 mice were not signiﬁcantly
different.
3.4 Blood pressure monitoring
Blood pressure transmitters with a catheter implanted in
the aortic arch were used to record mean arterial
pressure, pulse pressure, heart rate, systolic and diastolic
blood pressure, and activity of age-matched WT controls,
BM-transplanted eNOS
2/2 mice and non-transplanted
eNOS
2/2 controls (Figure 1B). Heart rate was signiﬁcantly
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2/2 mice compared with WT con-
trols (602+15 and 642+4 bpm, respectively, P , 0.05),
but was improved in eNOS
2/2 mice following BM transplan-
tation (642+14). No signiﬁcant differences in mean arterial
pressure or systolic and diastolic blood pressure were
observed between untreated eNOS
2/2 and BM-transplanted
eNOS
2/2 mice. In addition, there were no differences in
activity levels, assessed by lateral body movements over a
consecutive 100 h period, between BM-transplanted and
control groups suggesting that no apparent harmful effect
resulted from radiation, busulfan, and BM transplant
procedures.
3.5 Enhanced green ﬂuorescent protein positive
expression
High-level EGFP expression was detected by western blot
analysis in tissue lysates from heart, kidney, and spleen
obtained from transgenic EGFP control mice. Corresponding
tissues from untreated eNOS
2/2 mice were negative. The
heart and kidney from BM-transplanted eNOS
2/2 mice dis-
played low quantities of donor-derived EGFP (Figure 2A
and B). When values for EGFP transgenic mouse heart and
kidney were normalized to 1.0, we observed a three- to
four-fold greater band intensity in these mice compared
with BM-transplanted eNOS
2/2 mice. The spleens in
BM-transplanted eNOS
2/2 mice expressed high levels of
EGFP because their haematopoietic tissue was fully recon-
stituted by EGFP
þ donor cells.
3.6 DNA and mRNA analysis
DNA electrophoresis was performed on homogenates of
heart, kidney, and spleen from day-6, day-14 and day-28
BM-transplanted eNOS
2/2 mice. Banding patterns showed
trace quantities of WT eNOS (450 bp) in heart and kidney
of BM-transplanted eNOS
2/2 mice, whereas large quan-
tities of DNA encoding WT eNOS were observed in the
spleens of these mice (Figure 2C). The 500 bp band con-
sisted of 450 bp of exon 12 of the disrupted eNOS gene
plus 50 bp of the targeting construct. A similar pattern
emerged for EGFP DNA analysis (Figure 2D). The level of
mRNA expression in kidney, liver, and spleen was quantiﬁed
by RT–PCR using ß-actin as a loading control (Figure 2E and
F). EGFP and eNOS mRNA was highly expressed in trans-
genic EGFP
þ control tissues. Low levels of EGFP and WT
eNOS expression in kidney and liver of BM-transplanted
eNOS
2/2 mice were likely due to residual circulating
EGFP
þ donor-derived blood cells in these organs. In con-
trast to kidney and liver, the high-level expression of
EGFP mRNA in the spleen of BM recipients resulted from
donor cell reconstitution of the splenic haematopoietic
tissue. As in kidney and liver, WT eNOS mRNA (Figure 2F)
was low in spleen. Presumably, the EGFP
þ blood cells in
spleen did not express eNOS mRNA.
Figure 1 (A) Circulating white blood cells were analysed by ﬂow cytometry to determine the percent chimerism. (B) Haemodynamic parameters were assessed
4 months after BM transplantation and in age-matched controls by telemetry. Activity measures lateral movement. Heart rate and pulse pressure were increased
in BM-transplanted eNOS
2/2 mice vs. eNOS
2/2 controls. Mean+SD. *P , 0.05, **P,0.01.
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Sections of heart, kidney, liver, and spleen from transgenic
EGFP
þ control mice and BM-transplanted eNOS
2/2 recipi-
ents were stained with primary anti-EGFP and anti-SMaA
antibodies and ﬂuorophore-conjugated secondary anti-
bodies. Endothelial cells in arteries of EGFP
þ control mice
were consistently EGFP
þ (Figure 3A–D); however, no
EGFP
þ endothelial cells were found in corresponding
arteries in the chimeric BM-transplanted recipients
(Figure 3E–H). The same labelling pattern was observed
when aortas from transgenic and BM-transplanted
eNOS
2/2 mice were examined (Supplementary material
online, Figures S1A and B). No EGFP
þ endothelial cells
were seen in the ascending and descending aorta of
BM-transplanted eNOS
2/2 mice. Furthermore, terminal
arterioles in heart, kidney, liver, and spleen did not show
any evidence of incorporation of EGFP
þ endothelial cells
(Supplementary material online, Figure S2A–D). In an
additional effort to establish whether eNOS deﬁcient endo-
thelium can be renewed over time, we myeloablated WT
mice using busulfan then transplanted EGFP
þ BM cells and
reconstituted the recipient BM. One year after transplan-
tation, organs were harvested and examined for endothelial
cell renewal. No EGFP
þ endothelial cells were found in the
lining of conducting arteries and arterioles in heart,
kidney, and spleen (Supplementary material online, Figure
S3A–C) at 1 year after transplantation. Thus, the endothelial
linings of all arteries and arterioles examined in eNOS
2/2
mice, using multiple BM-transplanted protocols, remained
devoid of EGFP
þ cells.
Sections of heart, kidney, liver, and spleen were prepared
from transgenic EGFP
þ control mice and eNOS
2/2 BM
Figure 2 (A) EGFP expression was detected by western blot analysis in heart, kidney, and spleen of EGFP
þ controls and BM-transplanted eNOS
2/2 mice but not
in eNOS
2/2 control mice. (B) When values for EGFP
þ control heart and kidney were normalized to 1.0, we observed a three- to four-fold greater band intensity in
control mice compared with BM-transplanted eNOS
2/2 mice. (C) The 500 bp band represents amplicons consisting of 450 bp of the disrupted exon 12 of the eNOS
gene plus 50 bp of the targeting construct. The 450 bp band represents amplicons of the native eNOS gene. The label WT indicates amplicons of the wild-type
eNOS gene and KO indicates amplicons of the knockout (eNOS
2/2) gene. (C and D) DNA banding patterns for the amplicons of native eNOS (450 bp) and EGFP
(200 bp) in BM-transplanted mice indicated trace quantities present in both heart and kidney with high levels present in the reconstituted, haematopoietic
spleen. No differences were observed when DNA from day-6, day-14 and day-28 transplanted mice was analysed. (E and F) EGFP mRNA expression was low in
kidney and liver and high in the spleen, whereas expression of native eNOS mRNA was low in kidney, liver, and spleen. We believe the low-level eNOS mRNA
expression in the spleen reﬂects the abundance of EGFP
þ WBC that are positive for eNOS DNA but do not express eNOS mRNA and protein. Mean+SD;
EGFP
þ controls, n ¼ 3; BM-transplanted eNOS
2/2, n ¼ 4; eNOS
2/2 controls, n ¼ 4.
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day 28. The sections were stained with primary anti-EGFP
and anti-vWF antibodies and ﬂuorophore-conjugated sec-
ondary antibodies. Endothelial cells in arteries were consist-
ently positive for EGFP and vWF in transgenic donor mice
(Figure 4A–D). Corresponding arteries in BM-transplanted
eNOS
2/2 mice were typically devoid of EGFP
þ endothelial
cells, but like the WT control mice were uniformly positive
Figure 3 Confocal microscopy of conducting arteries in heart, kidney, liver,
and spleen in EGFP
þ control mice are seen in (A–D). Arteries from corre-
sponding organs in BM-transplanted eNOS
2/2 recipients are seen in (E–H).
It is clear that all endothelial cells (arrowheads) in the coronary, renal,
hepatic, and splenic arteries in the EGFP
þ control mice are EGFP
þ (green),
whereas no EGFP
þ endothelial cells are found in arteries of BM-transplanted
eNOS
2/2 mice. Several layers of smooth muscle cells are seen in the media
layer (red) of these arteries. This pattern of labelling is consistently observed
in all sections regardless of treatment protocol. Frequently, in areas near car-
diomyocytes (M), renal tubules (RT), and hepatocytyes (H), EGFP
þ WBC are
seen in capillaries and/or connective tissue (arrows). This is especially impor-
tant in the BM-transplanted eNOS
2/2 mice (E–H) as a conﬁrmation of main-
tained chimerism. In (G), a cross-section of a bile duct (BD) and a small
portion of a portal vein (V) are seen. The splenic pulp is densely packed
with EGFP
þ WBC (D and H). Green, EGFP; red, SMaA; yellow, merged EGFP
and SMaA; blue, Nuclei.
Figure 4 Confocal microscopy of conducting arteries in heart, kidney, liver,
and spleen in EGFP
þ control mice are seen (A–D). Arteries from corresponding
organs in BM-transplanted eNOS
2/2 recipients are seen (E–H). It is clear that
all endothelial cells in the coronary, renal, hepatic, and splenic arteries in the
EGFP
þcontrol miceareEGFP
þ(green),whereasnoEGFP
þendothelialcells are
foundinarteriesoftheBM-transplantedeNOS
2/2 mice.Thesectionswerealso
stained withanti-vWFantibodiesandallendothelialcellsexpressedvWF(red).
Several layers of smooth muscle cells are seen in the media (green) of the
arteries in EGFP
þ control mice. Endothelial cells in the coronary, renal,
hepatic, and splenic arteries (A–D) are positive for EGFP and vWF. Merged
images show yellow endothelial cells (arrowheads). The endothelium in the
BM-transplanted eNOS
2/2 mice is positive only for vWF and appears red. Fre-
quently,inareasnearcardiomyocytes(M)andrenaltubules(RT),EGFP
þdonor-
derived WBC are seen in capillaries and/or connective tissue (arrows). This is
especially important in the BM-transplanted eNOS
2/2 mice (E–H) as an indi-
cation of maintained chimerism. In (F), a small portion of a renal tubule (RT)
is seen. In (G), a small portion of the portal vein (V) and bile duct (BD) are
seen. The splenic pulp is densely packed with EGFP
þ WBC (D and H). Green,
EGFP; red, vWF; yellow, merged EGFP and vWF; blue, Nuclei.
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the aorta and conductive arteries from transgenic controls
and day-6 BM-transplanted eNOS
2/2 mice (Supplementary
material online, Figure S4A–C) were analysed for EGFP and
vWF expression. Collectively, these data indicate that the
endothelial lining of arteries is intact in the eNOS
2/2
model as seen by the presence of vWF expression throughout
the lining. However, these ﬁndings do not address the possi-
bility that donor cells are incorporated into the endothelium
but that EGFP expression is silenced in endothelial cells of
transplanted eNOS
2/2 mice.
To control for possible silencing of the EGFP gene in our
BM transplant protocols, we stained for eNOS expression in
the endothelium of EGFP transgenic mice and eNOS
2/2 BM
recipients. All endothelial cells in the aorta in transgenic
donors expressed eNOS (Figure 5A and C–E), but there was
no evidence for eNOS expression in the endothelial cells in
aortas of BM-transplanted recipients (Figure 5B).
3.8 Alternate treatments to determine toxicity
To test for toxicity induced by radiation and BM transplan-
tation, busulfan, a non-toxic myeloablative agent commonly
used in BM transplant therapy, was substituted as a myeloa-
blative agent prior to BM transplantation into eNOS
2/2
mice. We found no differences between busulfan-treated
and radiation-treated mice (Supplementary material
online, Figures S1B and S3A–C). Additionally, we trans-
planted day-6 and day-14 neonatal eNOS
2/2 mice, whose
growth rates were accelerated compared with day-28-
treated mice. There was no detectable evidence for EPC
incorporation into vascular endothelium in neonatal mice
or young adult mice when analysed for cardiovascular func-
tion by echocardiography, EGFP expression by molecular
assays, or structure by confocal microscopy.
4. Discussion
There is a body of literature supporting the concept that
BM-derived EPCs enter the circulation and contribute to
postnatal angiogenesis, neovascularization, and endothelial
cell renewal. We tested this concept in our study by asking
whether BM-transplanted progenitor cells from a healthy
donor might reconstitute the recipients BM and sub-
sequently replace dysfunctional endothelium in an animal
model with haemodynamic evidence of chronic endothelial
dysfunction. We found no evidence to suggest that trans-
planted BM cells replaced dysfunctional arterial endo-
thelium over time in an eNOS
2/2 mouse model of
hypertension.
BM cells from healthy EGFP
þ donors successfully reconsti-
tuted the BM of eNOS
2/2 mice when transplanted into sub-
lethally irradiated mice on day 28 after birth. Four months
after BM transplant, mean arterial pressure was not
reduced in these eNOS
2/2 mice, suggesting that few if
any EGFP
þ eNOS
þ donor-derived cells capable of producing
nitric oxide had incorporated into recipient endothelium.
Trace quantities of EGFP were detected by western blot in
hearts and kidneys of BM-transplanted eNOS
2/2 mice com-
pared with the control levels found in EGFP transgenic
mice. Failure to identify EGFP
þ endothelial cells in the
arteries and arterioles of these BM-transplanted mice, by
immunohistochemistry and confocal microscopy, suggested
to us that the low level of EGFP found in the hearts and
kidneys of recipient mice by western blot or DNA analysis
was contributed by residual WBCs in the circulation follow-
ing total body PBS perfusion and by WBCs in surrounding
extravascular connective tissue sites. We found support for
this interpretation by quantitative RT–PCR analysis of
eNOS expression in organs of recipient mice. eNOS mRNA,
Figure 5 Confocal microscopic images of several aortas are seen in (A–E).
The intima, which consists of a monolayer of endothelial cells, and the
media (M) are seen in (A–E). Nuclei in the endothelial cells of control
EGFP
þ mice (A) are embedded in eNOS positive (green) cytoplasm (arrow-
heads) and lie on the underlying internal elastic membrane that displays a
hint of green autoﬂuorescence (*). In contrast, nuclei in endothelial cells in
BM-transplanted eNOS
2/2 mice are ‘bare’ organelles (arrowheads) with no
visible cytoplasm and appear to lie on the underlying internal elastic mem-
brane (*) that displays a hint of (red) autoﬂuorscence (B). In (A) and (B),
green, eNOS; blue, nuclei. A portion of the endothelial and smooth muscle
layers of the aorta of an EGFP
þ control mouse is seen in (C–E). (E) In the
merged image, the double positive endothelial cytoplasm is yellow (arrow).
Green, EGFP; red, eNOS; yellow, merged EGFP and eNOS; blue, Nuclei.
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þ mice, was not readily detected in
organs of BM-transplanted eNOS
2/2 mice. Presumably, the
mature, circulating EGFP
þ blood cells in kidney and liver
produced little or no eNOS mRNA. Likewise, the numerous
developing and re-circulating mature EGFP
þ blood cells in
splenic haematopoietic tissue expressed no detectable
eNOS mRNA.
Contrary to the widely held concept that BM-derived, cir-
culating EPCs contribute to postnatal angiogenesis and neo-
vascularization, several recent reports claim that BM is not a
source of EPCs in arteriosclerotic grafts or in response to
hind-limb ischaemia.
16,17 Our data support these novel ﬁnd-
ings, in this highly controversial ﬁeld, by demonstrating a
lack of BM-derived endothelial cell incorporation into the
lining of the dysfunctional endothelium in eNOS
2/2 mice
during a 4 month period following BM transplantation.
However, we observed EGFP
þ cells near the outer arterial
wall of many vessels and within the adventitial layer, but
we did not assess whether these BM-derived EGFP
þ cells
were pericytes or monocytes engaged in paracrine
secretions as suggested by others.
18–25 According to this
hypothesis, pericytes or monocytes that reside within the
adventitia or occupy a vasculogenic zone at the interface
of the smooth muscle and adventitial layers of the artery
may monitor the behaviour of vasculogenic cells that
reside within the vessel wall.
25–27 This observation merits
additional investigation.
We considered the possibility that sub-lethal radiation fol-
lowed by BM transplantation was toxic to the eNOS
2/2 mice
in our study. Although this possibility cannot be fully
excluded, we did not ﬁnd evidence that radiation followed
by BM transplantation induced any long-term negative
effects. There was no decrease in body weight among the
BM-transplanted eNOS
2/2 mice compared with non-
transplanted eNOS
2/2 controls, and their physical activity
level was equal to that of the non-transplanted eNOS
2/2
mice and WT controls. Additionally, when busulfan, a non-
toxic myeloablative agent commonly used during BM trans-
plants in children, was substituted for radiation therapy, we
found no difference in cardiovascular structure and function
between these mice and the radiation-treated day-28 mice.
To further evaluate transplant protocols that might
product beneﬁt through endothelial renewal, we treated
day-6 and day-14 neonatal eNOS
2/2 mice, whose growth
rate and vascular expansion are accelerated in comparison
with day-28 transplanted mice, with sub-lethal radiation
and BM transplant. No detectable improvements in
outcome were observed when these younger mice were
compared with the older day-28-treated mice.
Our ﬁndings differ from those of an earlier study by
Guthrie et al.
28 in which GFP
þ BM was transplanted into
adult eNOS
2/2 mice following laser-induced retinal injury.
In this mouse model, EGFP
þ BM-derived cells gave rise to
retinal vasculature and, importantly, to EGFP
þ endothelium
in non-injured arteries in brain, thymus, and spleen. This
study and ours utilized eNOS
2/2 C57BL/6J mice and sub-
lethal radiation (6–6.5 Gy). Guthrie et al. enriched and
injected 2500 Sca-1
þ c-kit
þ lin
2 EGFP
þ BM cells, whereas
we injected 25   10e
7 nucleated BM cells in which the
Sca-1
þ c-kit
þ lin
2 phenotype occurs at a ratio of
1:100 000. Thus, both studies utilized 2500 EGFP
þ primitive
BM cells. In one major difference, photoagglutination of the
retinal vasculature may have produced an inﬂammatory or
cytokine response leading to systemic endothelial cell
damage and renewal. In our study, no injury was inﬂicted
during the time interval between sub-lethal radiation, BM
transplant, and tissue analysis. In another major difference,
Guthrie et al. stained 10 mm cryopreserved sections for con-
focal microscopy, whereas we examined 5 mm formalin ﬁxed
and parafﬁn embedded sections. The 5 mm formalin ﬁxed
sections provide greater resolution. We believe our proto-
col, which lacks induced vascular injury, may provide
useful pre-clinical data regarding the inability of EPCs to
renew endothelium in a setting of chronic endothelial cell
dysfunction and hypertension.
The BM transplant protocol was successful and the mice in
our study group showed blood cell chimerism greater than
85%. However, we did not ﬁnd evidence for incorporation
of BM-derived EGFP
þ cells into arterial or arteriolar endo-
thelium, nor were we able to improve hypertension in
BM-transplanted eNOS
2/2 mice. Hence, we conclude that
BM-derived cells, if they enter the circulation as EPCs, do
not participate in endothelial homeostasis and thus do not
repair chronic, systemic endothelial dysfunction in young
mice.
Supplementary material
Supplementary material is available at Cardiovascular
Research online.
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